DekaBank Deutsche Girozentrale
CTMX icon

DekaBank Deutsche Girozentrale’s CytomX Therapeutics CTMX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,100
Closed -$74K – 1393
2021
Q1 		$74K Hold
10,100
– – ﹤0.01% 1294
2020
Q4 		$70K Hold
10,100
– – ﹤0.01% 1289
2020
Q3 		$66K Buy
+10,100
New +$74.9K ﹤0.01% 1160
2019
Q3 		– Sell
-24,200
Closed -$257K – 1019
2019
Q2 		$257K Buy
24,200
+9,500
+65% +$99.6K ﹤0.01% 989
2019
Q1 		$334K Buy
14,700
+2,600
+21% +$38.4K ﹤0.01% 981
2018
Q4 		$178K Sell
12,100
-2,600
-18% -$38.6K ﹤0.01% 986
2018
Q3 		$334K Sell
14,700
-400
-3% -$9.11K ﹤0.01% 1003
2018
Q2 		$345K Sell
15,100
-12,000
-44% -$307K ﹤0.01% 979
2018
Q1 		$761K Buy
+27,100
New +$773K 0.01% 785

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

DekaBank Deutsche Girozentrale's CTMX Position: Q2 2021 in Review

DekaBank Deutsche Girozentrale sold out of CytomX Therapeutics (CTMX) in Q2 2021, closing a stake of 10,100 shares — an estimated $74K sold.

DekaBank Deutsche Girozentrale first reported a position in CTMX in Q1 2018 and held it in 9 quarters. The position peaked at $761K in Q1 2018. 122 funds tracked by Wall St. Rank hold CTMX as of Q2 2021.

  • DekaBank Deutsche Girozentrale reported no remaining CytomX Therapeutics position as of Q2 2021 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 10,100 CytomX Therapeutics shares in Q2 2021, an estimated $74K.
  • DekaBank Deutsche Girozentrale first reported a position in CytomX Therapeutics in Q1 2018 and held it in 9 quarters.
  • DekaBank Deutsche Girozentrale's CytomX Therapeutics position peaked at $761K in Q1 2018.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2021, filed 5 Aug 2021.